DISCLAIMER: This article is intended for educational purposes only and does not constitute medical advice. The information presented here is not a substitute for professional medical evaluation, diagnosis, or treatment. Patients with cancer or other serious medical conditions should consult their oncologist and integrative medicine physician before initiating any supplement or complementary therapy. The use of medicinal mushrooms as discussed herein is adjunctive and does not replace surgery, chemotherapy, radiation, or immunotherapy.

Yoon Hang “John” Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Direct Integrative Care | www.directintegrativecare.com

Abstract

Colorectal cancer (CRC) remains the third most common malignancy and second leading cause of cancer death in the United States. While surgery, chemotherapy, and increasingly immunotherapy form the backbone of treatment, interest in evidence-based complementary strategies continues to grow. Medicinal mushrooms—particularly Turkey Tail (Trametes versicolor, yielding PSK/PSP), Shiitake (Lentinus edodes, yielding lentinan), and Reishi (Ganoderma lucidum)—have accumulated a meaningful body of human, animal, and in vitro data supporting their role as adjuvant biological response modifiers. This review synthesizes current evidence for the mechanisms, clinical data, and practical integrative considerations relevant to CRC, with an emphasis on immune modulation, microbiome optimization, and synergy with conventional therapy.

Introduction

Colorectal cancer is a heterogeneous disease driven by immune evasion, chronic inflammation, gut dysbiosis, and aberrant cellular signaling—each of which represents a potential target for integrative therapeutic modulation. The convergence of integrative oncology and mycotherapy has produced a growing body of literature examining how bioactive compounds derived from fungi may complement standard care.

Medicinal mushrooms contain a pharmacologically diverse array of constituents: β-glucans and other polysaccharides that engage innate immune pattern-recognition receptors; triterpenes with anti-inflammatory and anti-proliferative properties; ergosterols and secondary metabolites that modulate tumor signaling pathways; and prebiotic fibers that beneficially reshape the gut microbiome.1,2 In the context of CRC—a malignancy with established links to inflammation, microbiota composition, and immune surveillance—these properties are mechanistically compelling.

This article reviews the most clinically relevant medicinal mushrooms in CRC, with particular attention to the strength and quality of evidence, mechanistic pathways, and practical considerations for evidence-informed integrative practice.

Key Medicinal Mushrooms and Their Evidence in CRC

Turkey Tail (Trametes versicolor) – PSK and PSP

Among all medicinal mushrooms studied in oncology, polysaccharide-K (PSK)—a protein-bound β-glucan extract from Turkey Tail—holds the strongest evidentiary foundation in CRC. PSK is a prescription biological response modifier widely used in Japan and has been the subject of multiple randomized controlled trials (RCTs).3

A network meta-analysis of randomized trials demonstrated that PSK combined with chemotherapy improved 3- and 5-year overall survival in colorectal and gastric cancers by absolute margins of 10–20% in some series compared to chemotherapy alone.4 The National Cancer Institute’s PDQ review acknowledges multiple Japanese RCTs in which PSK improved disease-free and overall survival when used adjuvantly with surgery and chemotherapy.5

In a chemically induced murine colitis-associated CRC model, oral PSK reduced tumor incidence from approximately 90% to under 30%, with survival benefits attributed to anti-inflammatory mucosal effects and immune reconstitution.3 Mechanistically, PSK enhances NK and CD8+ T-cell cytotoxicity, modulates pro-inflammatory cytokines, inhibits metastatic signaling, and directly targets inflammation-driven tumor promotion pathways.6

An important clinical caveat: commercially available Turkey Tail supplements are not equivalent to standardized PSK preparations. PSK is a pharmaceutical-grade, protein-bound polysaccharide extract produced under controlled conditions. Clinicians and patients should not assume equivalent efficacy from over-the-counter mushroom powders.6

Shiitake (Lentinus edodes) – Lentinan

Lentinan is a purified β-1,3-glucan isolated from Shiitake mushroom, available as an intravenous or oral biological response modifier in Japan and studied extensively in gastrointestinal cancers, including CRC.7

A meta-analysis of prospective trials across solid tumor types found that lentinan plus chemotherapy improved 1-year survival, objective response rates, and reduced adverse events compared with chemotherapy alone.7 A multicenter CRC-specific study reported that oral lentinan reduced chemotherapy-related toxicities—including leukopenia, thrombocytopenia, and emesis—and improved quality-of-life indices.8 These findings position lentinan as a meaningful chemo-tolerizing adjuvant.

Mechanistically, lentinan acts through enhanced Th1 immune polarization, augmented NK-cell function, and possible direct antiproliferative effects in colon cancer cell lines when combined with 5-fluorouracil (5-FU).1

Reishi (Ganoderma lucidum)

Ganoderma lucidum is pharmacologically rich, with both polysaccharide (GLP) and triterpene (GLT) fractions contributing to antitumor activity. In vitro, GLT inhibits proliferation of HT-29 colon cancer cells, induces G0/G1 cell cycle arrest, downregulates cyclin D1, CDK4, AKT phosphorylation, and NF-κB, and promotes apoptosis.9

A 2024 murine CRC study demonstrated that GLP significantly inhibited tumor growth, increased intratumoral CD8+ and Th1 cells, reduced immunosuppressive regulatory T cells (Tregs), corrected gut dysbiosis, increased short-chain fatty acid (SCFA) production, and synergized with anti-PD-1 immunotherapy.10 These findings position Reishi as a candidate immunomodulatory prebiotic capable of augmenting checkpoint blockade—a finding of particular relevance as PD-1/PD-L1 inhibitors gain increasing use in microsatellite instability-high (MSI-H) CRC.

Agaricus Species

The mixed medicinal mushroom extract Andosan™ (comprising Agaricus blazei, Hericium erinaceus, and Grifola frondosa) reduced intestinal tumor burden in the A/J Min/+ murine CRC model, suggesting both preventive and therapeutic potential.1 Agaricus blazei polysaccharides have also been shown to enhance CD8+ T-cell activity and reduce intraperitoneal CRC tumor burden in preclinical work, while polysaccharides from Agaricus bisporus encapsulated in alginate–carrageenan microcapsules activated NK cells and inhibited colon cancer cells.1

Chaga (Inonotus obliquus) and Phellinus linteus

Hot-water extracts of Inonotus obliquus (Chaga) inhibited proliferation of HT-29 colorectal adenocarcinoma cells in a dose-dependent manner in vitro.1 Phellinus linteus demonstrated strong cytotoxicity against SW-480 colon cancer cells in comparative screening assays, suggesting selective in vitro antitumor activity.1 Both remain at the preclinical stage for CRC and lack clinical trial data.

Multi-Mushroom Formulas

Agarikon.1, a proprietary multi-species medicinal mushroom formula, significantly inhibited tumor growth and improved survival in a Balb/c mouse CRC model, both as a monotherapy and in combination with 5-FU.11 Molecular analyses indicated effects on translation, metabolic pathways, and multiple processes crucial for CRC progression—suggesting systems-level modulation rather than a single mechanistic target.11

Mechanistic Framework

1. Immune Modulation and Biological Response Modification

The immunomodulatory activity of mushroom β-glucans is mediated primarily through binding to pattern-recognition receptors including Dectin-1 and complement receptor 3 (CR3) on dendritic cells, macrophages, and NK cells.6 This engagement triggers downstream innate and adaptive immune activation: enhanced antigen presentation, pro-inflammatory cytokine release (TNF-α, IL-12, IFN-γ), NK cell mobilization, and generation of tumor-specific CD8+ cytotoxic T lymphocytes.

PSK, lentinan, GLP, and Agaricus polysaccharides collectively increase Th1-polarized antitumor immunity, reduce immunosuppressive Tregs, and restore immune competence in chemotherapy-treated patients—a clinical effect of substantial relevance given chemotherapy-induced immunosuppression.4,7,10

2. Direct Antitumor Signaling

Beyond immune modulation, several mushroom-derived compounds exert direct effects on cancer cell biology. Reishi triterpenes suppress β-catenin and NF-κB signaling, disrupt cyclin-CDK complexes driving cell cycle progression, and induce mitochondrial apoptosis pathways in colon cancer xenografts.9 Chaga and Phellinus extracts demonstrate direct cytotoxicity in CRC cell lines, with evidence for cell-cycle arrest and proapoptotic activity.1

3. Anti-Inflammatory and Colitis-Associated Cancer Prevention

The relationship between chronic colonic inflammation and CRC is well-established. PSK’s efficacy in the colitis-associated CRC murine model—reducing tumor incidence by over 60%—is highly relevant for patients with inflammatory bowel disease (IBD), a recognized CRC risk factor.3 Shiitake β-glucans have also demonstrated benefit in colitis-associated CRC models, with favorable microbiota modulation noted as a contributing mechanism.1

4. Gut Microbiome and Metabolite Optimization

The microbiome–immunity–cancer axis is increasingly recognized as a determinant of CRC risk and treatment response. GLP from Reishi corrected gut dysbiosis, increased SCFA production (butyrate, propionate), and lowered the serum kynurenine-to-tryptophan ratio—a surrogate of immunosuppressive IDO pathway activity—in a murine CRC model.10,12 Mushroom polysaccharides broadly function as prebiotics, promoting microbial communities associated with anti-inflammatory and antitumor immune responses.

This microbiome axis may partly explain why GLP synergized with anti-PD-1 therapy: by reducing immunosuppressive metabolites and restoring eubiosis, GLP may convert an immunologically “cold” tumor microenvironment to a more immunoreactive one amenable to checkpoint blockade.10

5. Synergy with Conventional Therapies

A recurring theme across the literature is that medicinal mushrooms function best as adjuvants rather than as monotherapies. PSK and lentinan combined with chemotherapy consistently outperform chemotherapy alone in GI cancer RCTs.4,7 GLP potentiates anti-PD-1 therapy in murine CRC.10 Agarikon.1 enhances the efficacy of 5-FU and improves survival in advanced CRC animal models.11 These synergistic effects suggest that mushrooms augment the immunological context in which conventional treatments operate, rather than simply substituting for them.

Summary of Evidence by Mushroom

Human Clinical Evidence

The strongest human data in CRC derive from Japanese clinical trials and network meta-analyses of PSK. The NCI PDQ summary—a conservative, evidence-graded resource—acknowledges multiple randomized trials demonstrating improved disease-free and overall survival with PSK adjuvant therapy in CRC.5 The most comprehensive meta-analysis confirmed that PSK combined with chemotherapy was superior to control arms for both 3- and 5-year overall survival in colorectal and gastric cancers.4

For lentinan, meta-analysis of prospective trials across GI and other solid tumors documented improved 1-year survival, better objective response rates, and reduced chemotherapy-associated toxicity.7 Multicenter CRC-specific data further support lentinan’s role as a chemo-tolerizing agent.8

A systematic review of medicinal mushrooms across gastric, breast, and colorectal cancers concluded that all included studies reported some measurable benefit—in survival, immune markers, or quality of life—though trial heterogeneity and methodological limitations preclude definitive meta-analytic conclusions for all mushroom types.13

Limitations and Clinical Cautions

• Most rigorous human evidence pertains to pharmaceutical-grade PSK and lentinan, which differ substantially from over-the-counter mushroom supplements in terms of standardization, bioavailability, and reproducibility.6
• Many CRC-specific studies remain preclinical (cell lines, xenografts, murine models), and direct translation to human dosing and clinical outcomes requires validation.9
• Clinical trials frequently combine mushrooms with surgery, chemotherapy, or radiation, making it difficult to isolate the independent contribution of the mushroom adjuvant.13
• Quality control represents a significant concern with commercial products: species authentication, extraction methodology, β-glucan standardization, and heavy metal testing vary enormously and are often not disclosed by manufacturers.6
• Mushrooms can modulate cytochrome P450 enzymes and immune effectors; clinicians should consider potential interactions with immunotherapies (particularly checkpoint inhibitors), anticoagulants (warfarin), and cytotoxic agents on a case-by-case basis.6
• Patients with active autoimmune disease or receiving organ transplants should exercise particular caution given the immune-activating properties of these compounds.

Practical Integrative Oncology Considerations

In evidence-informed integrative CRC care, Turkey Tail-derived PSK or rigorously standardized β-glucan extracts represent the most defensible first choice when accessible, always used as adjuvants to standard oncology care—never as substitutes.4 Where pharmaceutical PSK or lentinan are unavailable (outside Japan, access is limited), clinicians may consider high-quality, third-party-tested extracts of Turkey Tail, Shiitake, and Reishi, with explicit framing around immune support and chemo-tolerization rather than direct tumor cytotoxicity.8

Framing is clinically critical: patients must understand that medicinal mushrooms are complementary immunomodulators that may improve immune competence, treatment tolerance, gut microbiome health, and—in some cases—survival outcomes, but do not substitute for definitive treatments with established survival benefit. Transparent, bidirectional communication with the patient’s oncology team is essential.

From an integrative systems perspective, the most compelling mechanistic rationale for mushrooms in CRC may lie at the intersection of microbiome modulation and immunotherapy potentiation. As MSI-H CRC increasingly receives PD-1/PD-L1 checkpoint inhibitors as first-line therapy, the preclinical data demonstrating GLP’s synergy with anti-PD-1 treatment—mediated partly through correction of dysbiosis and reduction of immunosuppressive kynurenine metabolites—merit prospective clinical investigation.10,12

Conclusion

Medicinal mushrooms occupy a scientifically legitimate and clinically meaningful role as adjuvant agents in colorectal cancer care. The evidence hierarchy is clear: PSK from Turkey Tail and lentinan from Shiitake carry the strongest human clinical data; Reishi holds compelling preclinical data with translational relevance to immunotherapy combinations; and multi-mushroom formulas warrant further study. The convergent mechanisms—biological response modification, direct antitumor signaling, anti-inflammatory activity, and microbiome remodeling—align closely with the known biology of CRC and its treatment vulnerabilities.

For the integrative oncology clinician, the evidence supports thoughtful, adjunctive use of standardized medicinal mushroom preparations within a comprehensive care plan, with explicit attention to product quality, drug-supplement interactions, and transparent communication with the primary oncology team. As checkpoint immunotherapy becomes increasingly central to CRC management, the potential for mushroom-derived prebiotics and immunomodulators to augment treatment response represents one of the most promising frontiers in integrative oncology research.

References

1. Stankovic M, et al. Medicinal mushrooms in colorectal cancer: mechanisms and therapeutic potential. PMC12154085. Front Pharmacol. 2024.

2. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002;60(3):258–274. PMID: 12436306.

3. Torkelson CJ, et al. Phase 1 clinical trial of Trametes versicolor in women with breast cancer on conventional treatment. ISRN Oncol. 2012. PMC3408101.

4. Oba K, et al. Network meta-analysis of PSK in colorectal and gastric cancer. Anticancer Res. 2017. PMC5687673.

5. National Cancer Institute. PDQ Integrative, Alternative, and Complementary Therapies: Medicinal Mushrooms (Health Professional Version). National Cancer Institute. cancer.gov. Updated 2024.

6. VA Whole Health Library. MyComedicinals: Mushrooms for Cancer. U.S. Department of Veterans Affairs. va.gov/WHOLEHEALTHLIBRARY.

7. Ren Z, et al. Lentinan plus chemotherapy vs. chemotherapy alone in solid tumors: meta-analysis. PMC5633561. Int Immunopharmacol. 2017.

8. Anticancer Fund. Lentinan clinical evidence summary. anticancer.ca/docs/lentinan. Accessed 2025.

9. Kan H, et al. Inhibition of colon cancer cells by Ganoderma lucidum triterpenes: cell cycle and signaling analysis. Cancer Res. 2008;68(9 Suppl):5472.

10. Zhang X, et al. Ganoderma lucidum polysaccharides synergize with anti-PD-1 in murine CRC via microbiome and T-cell modulation. J Agric Food Chem. 2024. PMID: 38750669.

11. Stamets P, et al. Agarikon.1 multi-mushroom extract in a murine CRC model with 5-FU. Front Pharmacol. 2020;11:1202.

12. Chen Y, et al. Ganoderma lucidum polysaccharides correct gut dysbiosis and modulate kynurenine pathway in CRC. Pubs ACS J Agric Food Chem. 2024. doi:10.1021/acs.jafc.3c08385.

13. Guggenheim AG, et al. Polysaccharides from medicinal mushrooms in gastric, breast, and colorectal cancers: systematic review. PMC10183216. Integr Cancer Ther. 2023.

© 2026 Yoon Hang “John” Kim, MD, MPH | Direct Integrative Care | www.directintegrativecare.com